French biopharma company Sanofi said it agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, UK, for up to $1.6 billion.
The deal would expand Sanofi’s respiratory vaccines pipeline.
“The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology,” said Sanofi.
Under the terms of the agreement, Sanofi would acquire all of Vicebio’s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements.
The transaction is expected to close in Q4 of 2025, subject to customary closing conditions, including receipt of regulatory approvals. The acquisition will not have a significant impact on Sanofi’s financial guidance for 2025.
“The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention,” said Sanofi.
“It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.
“In addition, the acquisition adds ‘Molecular Clamp’, an innovative technology that stabilizes viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively.
“This approach enables quicker development of fully liquid combination vaccines that can be stored at standard refrigeration temperatures (2–8°C), eliminating the need for freezing or freeze-drying, thereby simplifying manufacturing and distribution.
“Furthermore, fully liquid vaccines can be made available in prefilled syringes, enhancing ease of use, safety, and operational efficiency across healthcare settings.”
Jean-François Toussaint, Global Head of Research and Development Vaccines at Sanofi, said: “Vicebio’s ‘Molecular Clamp’ technology introduces a purposefully simple but thoughtfulapproach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally.
“This acquisition furthers Sanofi’s dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunization.”
Vicebio CEO Emmanuel Hanon said: “We are excited to join Sanofi. Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology.
“As part of the Sanofi team, we look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.”